Biotech | November 17, 2021
Pfizer seeks EUA from U.S. FDA for Covid-19 drug
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Filing marks first protein-based vaccine submitted to MHRA for authorization
Subscribe To Our Newsletter & Stay Updated
